Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia

• DOI: 10.1093/trstmh/trx021
• Publication Date: 2017-04-14T11:08:51Z
• Authors: Samanda Aponte; Ángela Patricia G...; Catalina Álvarez-...; Sindy Durley Bernal; César Restrepo; Camila González; María Fernanda Ya...; Angélica Knudson-...
• Keywords: Artemether/lumefantrine; Artemether; Lumefantrine; Dihydroartemisinin; Ex vivo

Colombia began using artemisinin-based combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in 2006. It is necessary to implement resistance surveillance antimalarial drugs order promptly detect changes parasite susceptibility. The aim this study was establish a susceptibility baseline P. artemether-lumefantrine three monitoring tools.Patients with treated underwent clinical and parasitological follow-up over 28 days. Ex vivo test performed microtest technique chloroquine, arthemeter, dihydroartemisinin lumefantrine. Pfmdr1 copy number polymorphisms Pfk13, Pfatp6, Pfcrt genes were analyzed.From total 150 screened patients, 49 completed All patients had adequate responses. Parasitic clearance showed drastic reduction biomass at 24 hours complete elimination 48 hours. One hundred eleven isolates processed, all exhibited high artemisinins slight decrease No genetic associated artemisinin found.This generated response therapy Coartem (artemether-lumefantrine) numerical reference values, which will allow data comparison future studies systematically monitor provide an early alert health authorities.